Latest News

Atlantic News

Atlantic Therapeutics receives €15 million in funding round

29th March 2017

Atlantic Therapeutics Group Ltd, the Galway-headquartered medical device developer of non-invasive pelvic floor strengthening and nerve stimulation products, has successfully completed a €15 million growth capital financing, enabling it to move forward with its next phase of growth and treat […]

Read More
Medlumics News

MedLumics Secures €34m in Series B Funding

20th March 2017

MedLumics, a cardiac device company specializing in optically guided minimally invasive instruments, announced today that it has raised 34.4 million Euros in financing that will be used to help advance the product and clinical development of the company’s AblaView catheter, […]

Read More
Pq Bypass News 2

PQ Bypass Announces CE Mark for DETOUR Percutaneous Bypass

13th March 2017

Seroba’s investee company, PQ Bypass, today announced CE (Conformité Européenne) Mark approval for a trio of proprietary devices: TORUS™ Stent Graft System, PQ Snare, and PQ Crossing Device, which enables physicians to perform a fully percutaneous femoral-popliteal bypass in patients […]

Read More
Prexton News

Prexton Therapeutics Series B financing round raises €29 million

17th February 2017

Prexton Therapeutics Series B financing round raises €29 million ($31M) to advance its novel Parkinson’s therapeutic.  Forbion & Seroba co-led the funding, forming an international consortium with Merck Ventures, Ysios and Sunstone.  Funding to finance two Phase II trials in Parkinson’s disease. Geneva, […]

Read More
Quanta Fluid News

Quanta Appoints World Leading Nephrologist to Medical Advisory Board

3rd February 2017

Seroba’s investee company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for the clinic and the home, today announces it has appointed Dr Sandip Mitra to its Medical Advisory Board. Sandip is […]

Read More
Opsona News 2

Preliminary results in Opsona’s myelodysplastic syndrome study

20th December 2016

Dublin, Ireland – Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat oncology, autoimmune and other inflammatory diseases, today announces the preliminary results from its ongoing prospective, open label Phase I/II study […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19

Scroll to Top